Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ICUBullishCorporate Developmentsnews

Medium materiality6/10

SeaStar Medical Advances QUELIMMUNE in Pediatric AKI, ICU Focus

Jul 14, 2026, 8:40 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Prominent promotional activity combined with favorable early data signals could lift sentiment and attract buyers, particularly on study-related milestones and conference mentions. Similar biotech promo events paired with supportive data have historically yielded short- to mid-term upside, though execution risk remains.

AI summary

What happened, with direct paths to the underlying reporting

SeaStar Medical sponsors the KidneyBee Summit and a QUELIMMUNE webinar to advance pediatric AKI treatment in the ICU. Citing Kidney Medicine data showing 77% survival versus standard care and SAVE Registry signals of 76% Day 28/60 survival with no device-related adverse events, the company positions QUELIMMUNE as a disease-modifying therapy with a favorable safety profile. The events could lift awareness, drive early adoption, and support near-term revenue potential.

SeaStar Medical sponsors KidneyBee Summit and QUELIMMUNE webinar in ICU.
QUELIMMUNE targets pediatric AKI; FDA-approved in 2024 under HDE.
Kidney Medicine data show 77% survival vs SOC; 87.5% Day 60 function.
SAVE Registry: first 21 patients show 76% Day 28/60 survival; no device-related adverse events.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.